Navigation Links
Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
Date:12/16/2010

SAN FRANCISCO and ILLKIRCH, France, Dec. 16, 2010 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that enrollment and treatment of patients in a Phase 1b clinical trial has been initiated to evaluate JX-594 in patients with advanced metastatic, refractory colorectal cancer (CRC).  The study will be performed in Korea, where Green Cross Corporation holds market rights for JX-594.

"The initiation of this study marks an important step forward in the development of JX-594 for a second major oncology indication. With a significant and growing population of colorectal cancer patients who have failed existing therapies or for whom existing therapies are not appropriate, we believe JX-594, with its unique mechanisms of action and demonstrated tumor response in preclinical models of CRC, may provide an important new therapeutic modality for patients around the world suffering from this devastating cancer," said David H. Kirn, M.D., president and chief executive officer of Jennerex.

"The study design for this trial builds on our joint experience and positive clinical results using JX-594 to treat liver cancer and represents an important milestone which is our ability to administer multiple doses intravenously," added Philippe Archinard, chairman and chief executive officer of Transgene.

The intravenous, open-label, multi-dose-escalation study is being conducted at Samsung Cancer Center in Seoul, South Korea. The study will enroll up to 15 patients with metastatic colorectal cancer that have failed both oxaliplatin-based and irinotecan-based chemotherapy regimens, and whose tumors harbor ras mutations and/ or are refractory to Erbitux therapy. Patients en
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
2. Jennerex Appoints Lara Longpre to Chief Operating Officer
3. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
4. Jennerex Announces Presentations at Upcoming Conferences
5. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
8. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
9. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
10. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
11. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... 2013 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... at ENDO 2013, the Endocrine Society,s 95 th ... (synchronize) both melatonin and cortisol rhythms. This effect ... body clock and address the circadian desynchrony which ... (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal ...
(Date:6/17/2013)... DNAtrix Inc., experts in oncolytic virus development, today announced ... company,s lead product, DNX-2401, at the Replicating Oncolytic Virus ... on June 18, 2013. Dr. ... the field of oncolytic virus therapy, will present results ... OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS DNX-2401 (FORMERLY KNOWN AS ...
(Date:6/17/2013)... 2013 BioMed Realty Trust, Inc. (NYSE: ... declared a second quarter 2013 dividend of $0.235 per share ... dividend of $0.94 per common share. The ... stockholders of record at the close of business on June ... BioMed Realty delivers optimal real estate solutions for biotechnology ...
Breaking Medicine Technology:Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3
... Pharmaceutical companies are dramatically increasing their investments ... demands of a patient-empowered, data-driven, outcomes-focused future in ... company investment in smart phone apps, educational websites, ... increased 78%, as companies embrace a role that ...
... Inc. (Nasdaq: MLAB ) today announced that ... cash dividend of 12 cents per share of common ... record at the close of business on February 25, ... markets electronic instruments and disposables for industrial, pharmaceutical and ...
Cached Medicine Technology:Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 2Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 3Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 4Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 5
(Date:6/18/2013)... New York (PRWEB) June 18, 2013 As ... both state and federal court, a new report has revealed ... than 70,000 U.S. Food & Drug Administration (FDA) adverse event ... to NewsChannel5 in Cleveland, Ohio, over 4.700 Mirena users have ... while more than 1,300 have reportedly experienced uterine perforations due ...
(Date:6/18/2013)... 2013 New York magazine named 145 physicians ... “Best Doctors” list, up from 129 last year and more ... issue also lists 52 additional doctors who serve at hospitals ... growth trajectory. The “Best Doctors” issue, which this year features ... print issue and is available online at http://www.nymag.com/bestdoctors . ...
(Date:6/18/2013)... York, N.Y., June 18, 2013 -- Lauren Sciences, ... novel V-Smart nanovesicle platform technology, announced today that ... in Drug Delivery with its V-Smart Platform, and ... report by MCD Group. , The ... of Start-ups and Emerging Companies ," features companies ...
(Date:6/18/2013)... their scheduled medical appointments and their disease under ... things clearly and knows them as a person, not ... "If people feel their doctor really knows them and ... best interests at heart and may be more likely ... Flickinger, M.D., M.P.H., a fellow in the Division of ...
(Date:6/18/2013)... officially declared June as Lesbian, Gay, Bisexual ... advances in civil rights, sexual minority youth ... than their heterosexual peers, according to the ... Missouri psychology graduate student recently published recommendation ... youth, which could help improve psychological functioning ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 3Health News:Respect may be the key to stopping patient 'no shows' 2Health News:Sexual minority youth need specialized treatment from therapists 2
... 10 New and innovative,programs to obtain donor organs ... example, transplant experts are studying a,program they call "living ... friend of a kidney-transplant,patient who is not compatible as ... also may be an incompatible match for his or ...
... old dog new tricks: antimalarial prevents cancer in mice ... researchers from St Jude Childrens Research Hospital, Memphis, and ... drug chloroquine effectively prevents cancer in mouse models of ... telangiectasia. As discussed in the accompanying commentary by Chi ...
... legs can come after infection or cancer therapy, researchers note ... adrenomedullin may prove an effective drug target for treating lymphedema, ... cancer or other cancer treatment, U.S. researchers say. , It ... a team from the University of North Carolina at Chapel ...
... impact boys more than girls, national survey finds , , ... do work to help discourage many teens from becoming ... Wednesday by the U.S. Centers for Disease Control and ... presented in schools and church groups -- did appear ...
... specialty brings more efficient, yet equally safe, patient management, ... A new breed of medical specialists, called hospitalists, can ... long a patient needs to stay in the hospital, ... almost 77,000 hospital stays at 45 centers showed that ...
... Sonography Technology(TM) Developer Cited Number One in Image Quality, ... Ergonomics and ... developer of premium ultrasound systems, today announced it has been,ranked Best ... the,KLAS Top20: Year-End Report published this week. Previously, the company,was ranked ...
Cached Medicine News:Health News:UCLA Program Aims to Revolutionize Kidney Transplants 2Health News:JCI table of contents: Dec. 20, 2007 2Health News:JCI table of contents: Dec. 20, 2007 3Health News:JCI table of contents: Dec. 20, 2007 4Health News:JCI table of contents: Dec. 20, 2007 5Health News:JCI table of contents: Dec. 20, 2007 6Health News:JCI table of contents: Dec. 20, 2007 7Health News:JCI table of contents: Dec. 20, 2007 8Health News:Hormone Could Ease Painful Lymphedema 2Health News:Sex Ed Does Delay Teen Sex: CDC 2Health News:Sex Ed Does Delay Teen Sex: CDC 3Health News:Sex Ed Does Delay Teen Sex: CDC 4Health News:'Hospitalist' Physicians Help Shorten Patient Stays 2Health News:'Hospitalist' Physicians Help Shorten Patient Stays 3Health News:ZONARE Ranked Best in KLAS as Hand Carried Ultrasound Vendor in 2007 Top20: Year-End Report 2Health News:ZONARE Ranked Best in KLAS as Hand Carried Ultrasound Vendor in 2007 Top20: Year-End Report 3
... 1.6 Titanium Cranial Fixation Systems incorporate ... specifically requested by surgeons and surgical ... implants may be either shaped on ... warrants, a pre-measured, cut, bent and ...
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery....
... DBM Matrix PLF is ... material designed specifically for ... trough-like design allows for ... bone. Demineralized bone fibers ...
Demineralized bone matrix dispensed in a syringe. DBM will be free of foreign matter. Demineralized bone matrix particle size 125 to 850 . Glycerol 70-88% by weight. Calcium content less than 8%....
Medicine Products: